SLNO SOLENO THERAPEUTICS INC

Nasdaq soleno.life


$ 47.73 $ -0.38 (-0.8 %)    

Thursday, 13-Nov-2025 16:00:01 EST
QQQ $ 608.59 $ -9.26 (-1.5 %)
DIA $ 475.50 $ -6.59 (-1.37 %)
SPY $ 672.57 $ -8.41 (-1.24 %)
TLT $ 89.38 $ -0.42 (-0.46 %)
GLD $ 384.40 $ -4.31 (-1.11 %)
$ 47.35
$ 47.29
$ 47.00 x 15
$ 49.83 x 200
-- - --
$ 41.50 - $ 90.32
1,489,499
na
2.54B
$ 3.50
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 02-28-2025 01-01-1970 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-07-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-22-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-10-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 03-31-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 07-28-2021 06-30-2021 10-Q
19 05-05-2021 03-31-2021 10-Q
20 03-03-2021 12-31-2020 10-K
21 11-10-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-12-2020 03-31-2020 10-Q
24 03-04-2020 12-31-2019 10-K
25 11-13-2019 09-30-2019 10-Q
26 08-07-2019 06-30-2019 10-Q
27 05-13-2019 03-31-2019 10-Q
28 03-20-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
31 05-15-2018 03-31-2018 10-Q
32 04-02-2018 12-31-2017 10-K
33 11-14-2017 09-30-2017 10-Q
34 08-11-2017 06-30-2017 10-Q
35 05-11-2017 03-31-2017 10-Q
36 03-15-2017 12-31-2016 10-K
37 11-14-2016 09-30-2016 10-Q
38 08-12-2016 06-30-2016 10-Q
39 05-12-2016 03-31-2016 10-Q
40 03-25-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 soleno-therapeutics-unveils-100-million-buyback-citing-underappreciated-future

Soleno Therapeutics (SLNO) approved $100M share repurchase program & entered ASR agreement with Jefferies LLC to buy back i...

 soleno-therapeutics-announces-100m-accelerated-share-repurchase-plan

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

 wells-fargo-maintains-overweight-on-soleno-therapeutics-lowers-price-target-to-106

Wells Fargo analyst Derek Archila maintains Soleno Therapeutics (NASDAQ:SLNO) with a Overweight and lowers the price target ...

 soleno-therapeutics-q3-eps-047-beats-006-estimate-sales-66000m-beat-48095m-estimate

Soleno Therapeutics (NASDAQ:SLNO) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $...

 acadia-pharma-faces-trial-setback-as-prader-willi-syndrome-trial-falls-short

Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales...

 soleno-therapeutics-says-aware-of-serious-adverse-event-in-fdas-faers-regarding-patient-who-died-case-reported-as-not-related-to-vykat-xr-treatment-patient-was-a-17-year-old-male-who-died-from-pulmonary-embolus-vykat-xr-has-proven-safety-and-efficacy-profile

-SEC Filing

 scorpion-capital-posts-on-x-that-it-remains-short-soleno-therapeutics

https://x.com/ScorpionFund/status/1960731687903498571

 guggenheim-reiterates-buy-on-soleno-therapeutics-maintains-106-price-target

Guggenheim analyst Debjit Chattopadhyay reiterates Soleno Therapeutics (NASDAQ:SLNO) with a Buy and maintains $106 price tar...

 wells-fargo-initiates-coverage-on-soleno-therapeutics-with-overweight-rating-announces-price-target-of-123

Wells Fargo analyst Derek Archila initiates coverage on Soleno Therapeutics (NASDAQ:SLNO) with a Overweight rating and annou...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION